Cure8 research brief
Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be individualized.
Adults with ulcerative colitis or Crohn’s disease considering treatment reduction, patients currently on biologics or oral advanced therapies, and the clinicians who manage them.
This Frontline Gastroenterology piece reviews the evidence and limitations around de-escalation (stepping down or withdrawing therapy) in ulcerative colitis and Crohn’s disease. Most of the available data come from anti‑TNF agents; evidence for newer biologics and oral small molecules is more limited.
Relapse rates after stopping treatment are described as substantial, and there are currently no reliable predictors that guarantee long-term treatment‑free remission.
The authors recommend that de‑escalation decisions integrate disease phenotype, prior disease history, and objective markers of inflammatory control (for example blood tests and fecal calprotectin), together with patient preferences. They emphasise the variable strength of the evidence and the need for individualized decision‑making.
Practical takeaways include using objective monitoring when considering de‑escalation and discussing the substantial relapse risk with patients so they can weigh trade-offs.
The article is a journal review/clinical perspective summarising available studies (mostly anti‑TNF data) rather than reporting new trial results. Evidence for newer drugs and reliable predictors of long‑term drug‑free remission is limited.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
